Verona Pharma plc is a United Kingdom-based bio-pharmaceutical company. The Company is engaged in developing drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its program is RPL554, an inhaled, dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitors, as a nebulized treatment for patients in hospital with acute exacerbation of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. RPL554 has completed two double-blind placebo controlled randomized Phase II b studies of RPL554: one in mild to moderate asthma and another in mild to moderate COPD. Its other products include VRP700 and NAIPs. VRP700 is an anti-tussive (cough) drug and has completed a Phase II trial. The Company's subsidiaries include Rhinopharma Limited and Verona Pharma Inc.
Type
Public
HQ
London, GB
Size (employees)
7 (est)
Verona Pharma is headquartered in London, GB
Report incorrect company information

Verona Pharma Office Locations

Verona Pharma has offices in London and Cardiff
London, GB (HQ)
3 More London Riverside
Cardiff, GB
Bradley Court, Park Place
Show all (2)
Report incorrect company information

Verona Pharma Financials and Metrics

Verona Pharma Financials

GBP

Net income (FY, 2017)

(20.5 m)

EBITDA (FY, 2017)

(29.7 m)

EBIT (FY, 2017)

(29.8 m)

Market capitalization (24-Oct-2017)

125.3 m

Closing share price (24-Oct-2017)

1.5

Cash (31-Dec-2017)

31.4 m
Verona Pharma's current market capitalization is £125.3 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

EBITDA

(1.3 m)(1.5 m)(1.6 m)(1.9 m)(1.8 m)(2.6 m)(2.8 m)(3.7 m)(8.9 m)(6.9 m)(29.7 m)

EBIT

(1.3 m)(1.5 m)(1.6 m)(1.9 m)(1.8 m)(2.6 m)(2.8 m)(3.8 m)(9 m)(7 m)(29.8 m)

Pre tax profit

(1.2 m)(1.3 m)(1.6 m)(1.9 m)(1.8 m)(2.6 m)(2.8 m)(3.8 m)(9 m)(6 m)(25.2 m)

Income tax expense

(27.9 k)(4.5 k)124.4 k48.1 k289.4 k1 m1.5 m954 k4.7 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.3 m2.5 m2.8 m2 m2.5 m960.9 k603.8 k10 m3.5 m39.8 m31.4 m

Current Assets

1.5 m2.5 m3.2 m2.1 m2.6 m1.2 m853.4 k11.3 m5.6 m43.8 m87.1 m

PP&E

16.1 k14.1 k18 k15.5 k6 k39.5 k27.6 k21.8 k13.2 k14 k16 k

Goodwill

1.8 m2.3 m2.3 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(1.2 m)(1.4 m)(1.6 m)(1.9 m)(1.7 m)(2.5 m)(2.5 m)(2.8 m)(7.5 m)(5 m)(20.5 m)

Cash From Operating Activities

1.2 m(1.3 m)(1.6 m)(1.7 m)(1.7 m)(2.6 m)(2.3 m)(3.5 m)(6.4 m)(5.6 m)(20.7 m)

Cash From Financing Activities

2.4 m2 m873.9 k2.1 m1 m1.8 m13.1 m41.2 m63.2 m

Net Change in Cash

188.8 k1.2 m375.1 k(827 k)523.2 k(1.6 m)(357.1 k)9.4 m(6.4 m)35.6 m(6.9 m)
GBPY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Verona Pharma News and Updates

Report incorrect company information